Pluristem Therapeutics, Inc. announced that the Paul-Ehrlich-Institute (PEI) has approved the company's request to initiate a phase II study using PLX-PAD cells in patients suffering from Intermittent Claudication. IC is a subset of Peripheral Artery Disease (PAD).